AstraZeneca PLC Morgan Bond
ZEGA Stock | EUR 64.50 1.00 1.57% |
AstraZeneca PLC has over 22.96 Billion in debt which may indicate that it relies heavily on debt financing. . AstraZeneca PLC's financial risk is the risk to AstraZeneca PLC stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
AstraZeneca PLC's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. AstraZeneca PLC's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps AstraZeneca Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect AstraZeneca PLC's stakeholders.
For most companies, including AstraZeneca PLC, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for AstraZeneca PLC, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, AstraZeneca PLC's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
AstraZeneca |
Given the importance of AstraZeneca PLC's capital structure, the first step in the capital decision process is for the management of AstraZeneca PLC to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of AstraZeneca PLC to issue bonds at a reasonable cost.
Popular Name | AstraZeneca PLC Morgan Stanley 3971 |
Equity ISIN Code | US0463531089 |
Bond Issue ISIN Code | US61744YAL20 |
S&P Rating | Others |
Maturity Date | 22nd of July 2038 |
Issuance Date | 24th of July 2017 |
Coupon | 3.971 % |
AstraZeneca PLC Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
ASTRAZENECA PLC 645 | US046353AD01 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
ASTRAZENECA PLC 3375 | US046353AL27 | Details | |
ASTRAZENECA PLC 4375 | US046353AM00 | Details | |
ASTRAZENECA PLC 4 | US046353AG32 | Details | |
ASTRAZENECA PLC 4 | US046353AT52 | Details | |
ASTRAZENECA PLC 4375 | US046353AU26 | Details | |
ASTRAZENECA PLC 3125 | US046353AN82 | Details | |
ASTRAZENECA PLC | US046353AV09 | Details | |
ASTRAZENECA PLC | US046353AW81 | Details | |
ASTRAZENECA PLC | US046353AZ13 | Details | |
AZN 4875 03 MAR 28 | US04636NAF06 | Details | |
ASTRAZENECA FINANCE LLC | US04636NAE31 | Details | |
AZN 49 03 MAR 30 | US04636NAG88 | Details | |
ASTRAZENECA FINANCE LLC | US04636NAA19 | Details | |
ASTRAZENECA FINANCE LLC | US04636NAB91 | Details | |
AZN 4875 03 MAR 33 | US04636NAH61 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details |
Understaning AstraZeneca PLC Use of Financial Leverage
AstraZeneca PLC's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures AstraZeneca PLC's total debt position, including all outstanding debt obligations, and compares it with AstraZeneca PLC's equity. Financial leverage can amplify the potential profits to AstraZeneca PLC's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if AstraZeneca PLC is unable to cover its debt costs.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. ASTRAZENECA operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 64400 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.